Halozyme Therapeutics Inc. [NASDAQ: HALO] surged by $5.79 during the normal trading session on while it closed the day at $51.44.
Halozyme Therapeutics Inc. stock has also gained 18.66% of its value over the past 7 days. However, HALO stock has inclined by 23.33% in the 3 months of the year. Over the past six months meanwhile, it has gained 28.92% and gained 39.18% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for HALO stock reached $6.55 billion, with 126.77 million shares outstanding and 125.85 million shares in the current float. Compared to the average trading volume of 962.45K shares, HALO reached a trading volume of 4597834 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Halozyme Therapeutics Inc. [HALO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HALO shares is $52.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HALO stock is a recommendation set at 1.36. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Halozyme Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 29, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 24, 2023, representing the official price target for Halozyme Therapeutics Inc. stock. Previously, the target price had yet another raise from $43 to $45, while Goldman kept a Neutral rating on HALO stock.
The Average True Range (ATR) for Halozyme Therapeutics Inc. is set at 1.71, with the Price to Sales ratio for HALO stock in the period of the last 12 months amounting to 7.59. The Price to Book ratio for the last quarter was 36.79, with the Price to Cash per share for the same quarter was set at 3.64. Price to Free Cash Flow for HALO in the course of the last twelve months was 15.46 with Quick ratio for the last quarter at 5.36.
HALO stock trade performance evaluation
Halozyme Therapeutics Inc. [HALO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.66. With this latest performance, HALO shares gained by 24.82% in over the last four-week period, additionally plugging by 28.92% over the last 6 months – not to mention a rise of 51.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HALO stock in for the last two-week period is set at 77.83, with the RSI for the last a single of trading hit 82.16, and the three-weeks RSI is set at 74.46 for Halozyme Therapeutics Inc. [HALO]. The present Moving Average for the last 50 days of trading for this stock 41.62, while it was recorded at 46.15 for the last single week of trading, and 38.95 for the last 200 days.
Halozyme Therapeutics Inc. [HALO]: An insightful look at the core fundamentals
Halozyme Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.36 and a Current Ratio set at 6.64.
Earnings per share (EPS) analysis for Halozyme Therapeutics Inc. [HALO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HALO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Halozyme Therapeutics Inc. go to 26.00%.
Halozyme Therapeutics Inc. [HALO]: Institutional Ownership
The top three institutional holders of HALO stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in HALO stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in HALO stock with ownership which is approximately 5.8386%.
